Dimerix Stock

Dimerix ROE

The Return on Equity (ROE) of Dimerix (DXB.AX) as of Jul 15, 2026 is -99.05 %. In the previous year, Return on Equity (ROE) was -93.89 % — a change of 5.49% (lower).

ROE

-99.05 %

YoY

5.49%

Last updated:

In 2026, Dimerix's return on equity (ROE) was -99.05 %, a 5.49% increase from the -93.89 % ROE in the previous year.

Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

ROE Details

Decoding Dimerix's Return on Equity (ROE)

Dimerix's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Dimerix's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Dimerix's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Dimerix’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Dimerix stock

Return on Equity (ROE) of Dimerix is -99.05 % in 2026.

Access this data via the Eulerpool API

Profitability — Dimerix

All Key Metrics — Dimerix